TIGECYCLINE

N/A

Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

10,584 FDA adverse event reports analyzed

Last updated: 2026-04-15

About TIGECYCLINE

TIGECYCLINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. The most commonly reported adverse reactions for TIGECYCLINE include DRUG INEFFECTIVE, OFF LABEL USE, NAUSEA, VOMITING, SEPSIS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TIGECYCLINE.

Top Adverse Reactions

DRUG INEFFECTIVE720 reports
OFF LABEL USE649 reports
NAUSEA391 reports
VOMITING268 reports
SEPSIS265 reports
THROMBOCYTOPENIA254 reports
DEATH252 reports
SEPTIC SHOCK227 reports
DRUG RESISTANCE210 reports
DIARRHOEA202 reports
PATHOGEN RESISTANCE202 reports
COAGULOPATHY195 reports
CONDITION AGGRAVATED190 reports
PLATELET COUNT DECREASED167 reports
PRODUCT USE IN UNAPPROVED INDICATION167 reports
PYREXIA166 reports
ACUTE KIDNEY INJURY158 reports
PANCREATITIS ACUTE149 reports
PANCREATITIS147 reports
TREATMENT FAILURE139 reports
DRUG INTERACTION132 reports
PNEUMONIA125 reports
RENAL FAILURE123 reports
HYPOTENSION119 reports
BLOOD BILIRUBIN INCREASED109 reports
ANAEMIA107 reports
RENAL IMPAIRMENT105 reports
RESPIRATORY FAILURE105 reports
KLEBSIELLA INFECTION102 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME102 reports
NEUTROPENIA101 reports
HYPOFIBRINOGENAEMIA93 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS90 reports
RASH90 reports
BLOOD FIBRINOGEN DECREASED88 reports
ALANINE AMINOTRANSFERASE INCREASED86 reports
FATIGUE86 reports
DYSPNOEA85 reports
ABDOMINAL PAIN84 reports
DECREASED APPETITE83 reports
MULTI ORGAN FAILURE80 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION78 reports
INFECTION77 reports
BLOOD CREATININE INCREASED76 reports
HEPATIC FAILURE76 reports
LIVER INJURY76 reports
STAPHYLOCOCCAL INFECTION76 reports
GASTROINTESTINAL DISORDER75 reports
ASPARTATE AMINOTRANSFERASE INCREASED74 reports
HEPATIC FUNCTION ABNORMAL74 reports
ENTEROCOCCAL INFECTION73 reports
DRUG INDUCED LIVER INJURY70 reports
GASTROINTESTINAL HAEMORRHAGE70 reports
WHITE BLOOD CELL COUNT DECREASED69 reports
PSEUDOMONAS INFECTION68 reports
ACINETOBACTER INFECTION67 reports
DRUG HYPERSENSITIVITY66 reports
TRANSAMINASES INCREASED66 reports
HEPATOTOXICITY65 reports
WEIGHT DECREASED64 reports
CANDIDA INFECTION62 reports
HYPOGLYCAEMIA62 reports
BLOOD ALKALINE PHOSPHATASE INCREASED61 reports
BACTERIAL INFECTION60 reports
BLOOD UREA INCREASED58 reports
HEPATIC ENZYME INCREASED58 reports
BACTERAEMIA57 reports
CHOLESTASIS56 reports
ELECTROCARDIOGRAM QT PROLONGED56 reports
MALAISE56 reports
DRUG INTOLERANCE55 reports
GENERAL PHYSICAL HEALTH DETERIORATION55 reports
HAEMOGLOBIN DECREASED55 reports
CLOSTRIDIUM DIFFICILE COLITIS54 reports
LEUKOPENIA54 reports
PRODUCT USE ISSUE54 reports
PANCYTOPENIA53 reports
RHABDOMYOLYSIS53 reports
DISEASE PROGRESSION52 reports
ASTHENIA50 reports
HAEMORRHAGE50 reports
CARDIAC ARREST49 reports
LIPASE INCREASED48 reports
NEUROPATHY PERIPHERAL48 reports
PRURITUS48 reports
TOXICITY TO VARIOUS AGENTS48 reports
FEBRILE NEUTROPENIA47 reports
MYCOBACTERIUM ABSCESSUS INFECTION47 reports
C REACTIVE PROTEIN INCREASED46 reports
MULTIPLE DRUG RESISTANCE44 reports
RENAL FAILURE ACUTE44 reports
DYSBIOSIS43 reports
DEAFNESS42 reports
WHITE BLOOD CELL COUNT INCREASED42 reports
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED41 reports
COAGULATION TIME PROLONGED41 reports
GAMMA GLUTAMYLTRANSFERASE INCREASED41 reports
HYPERKALAEMIA41 reports
AGRANULOCYTOSIS40 reports
ERYTHEMA40 reports

Report Outcomes

Out of 5,878 classified reports for TIGECYCLINE:

Serious 92.7%Non-Serious 7.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male2,949 (56.5%)
Female2,229 (42.7%)
Unknown40 (0.8%)

Reports by Age

Age 66122 reports
Age 69110 reports
Age 70109 reports
Age 67106 reports
Age 63102 reports
Age 5797 reports
Age 6496 reports
Age 6295 reports
Age 7488 reports
Age 5987 reports
Age 6586 reports
Age 7186 reports
Age 6884 reports
Age 7281 reports
Age 6180 reports
Age 5679 reports
Age 7577 reports
Age 8076 reports
Age 5875 reports
Age 7675 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with TIGECYCLINE?

This profile reflects 10,584 FDA FAERS reports that mention TIGECYCLINE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for TIGECYCLINE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, NAUSEA, VOMITING, SEPSIS, THROMBOCYTOPENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures TIGECYCLINE?

Labeling and FAERS entries often list Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. in connection with TIGECYCLINE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.